​

Lite Strategy Stock (NASDAQ:LITS)

FinancialsChart
Lite Strategy by TradingView

Previous Close

$1.78

52W Range

$1.46 - $9.00

50D Avg

$2.27

200D Avg

$2.83

Market Cap

$60.61M

Avg Vol (3M)

$1.00M

Beta

0.05

Div Yield

-

LITS Company Profile

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Dec 18, 2003

Website

LITS Performance

LITS Financial Summary

Jun 25Jun 24Jun 23
Revenue-$65.30M$48.82M
Operating Income$-17.45M$14.54M$-36.76M
Net Income$-15.95M$17.78M$-31.84M
EBITDA$-17.09M$25.82M$-36.38M
Basic EPS$-2.39$2.67$-4.78
Diluted EPS$-2.39$2.67$-4.78

Fiscal year ends in Jun 25 | Currency in USD

Peer Comparison

TickerCompany
TCRXTScan Therapeutics, Inc.
IOBTIO Biotech, Inc.
PMVPPMV Pharmaceuticals, Inc.
NTRBNutriband Inc.
HOWLWerewolf Therapeutics, Inc.
XBITXBiotech Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
IMUXImmunic, Inc.
ACETAdicet Bio, Inc.
RLMDRelmada Therapeutics, Inc.